Heron Therapeutics is trading down 5.6% at $0.29, with no confirmed company-specific catalyst identified for October 26, 2026.
- The latest release listed on the company’s investor-relations site is its August 10 second-quarter results.
- Major indexes are modestly higher, not showing a broad decline that explains the move.
- Recent sessions were volatile, but available evidence does not establish a cause for the current drop.